Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications.

H. Vlassara, M. Brownlee, A. Cerami

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Prolonged hyperglycemia is the primary metabolic abnormality responsible for the development of irreversible tissue damage in chronic diabetes. However, patients with similar levels of chronic hyperglycemia can differ markedly in their susceptibility to diabetic complications. Among the mechanisms by which hyperglycemia may lead to tissue damage, nonenzymatic glycosylation involves excessive chemical attachment of glucose to proteins without the involvement of enzymes. The early Amadori products, resembling hemoglobin A1c, slowly give rise to complex irreversible glycosylation adducts. Only these post-Amadori products accumulate in diabetic tissues over long periods. However, early nonenzymatic glycosylation or Amadori product formation can alter such physiological processes as enzyme activity or binding of regulatory molecules. Advanced glycosylation end products can covalently trap extravasated serum proteins to the extravascular matrix, and thus may contribute to capillary closure in the retina and glomerulus, and to arterial narrowing in the coronary, cerebral, and peripheral circulation. Although a macrophage receptor system may antagonize this glycosylation-mediated accumulation of proteins by recognizing and ingesting those proteins with advanced glycosylation end products, excessive formation of those proteins in diabetes may saturate the capacity of the macrophage removal system.

Original languageEnglish (US)
JournalClinical Chemistry
Volume32
Issue number10 Suppl
StatePublished - Oct 1986
Externally publishedYes

Fingerprint

Glycosylation
Diabetes Complications
Hyperglycemia
Advanced Glycosylation End Products
Macrophages
Tissue
Medical problems
Cerebrovascular Circulation
Proteins
Physiological Phenomena
Enzyme activity
Enzymes
Retina
Blood Proteins
Hemoglobins
Glucose
Molecules

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Vlassara, H., Brownlee, M., & Cerami, A. (1986). Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. Clinical Chemistry, 32(10 Suppl).

Nonenzymatic glycosylation : role in the pathogenesis of diabetic complications. / Vlassara, H.; Brownlee, M.; Cerami, A.

In: Clinical Chemistry, Vol. 32, No. 10 Suppl, 10.1986.

Research output: Contribution to journalArticle

Vlassara, H, Brownlee, M & Cerami, A 1986, 'Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications.', Clinical Chemistry, vol. 32, no. 10 Suppl.
Vlassara, H. ; Brownlee, M. ; Cerami, A. / Nonenzymatic glycosylation : role in the pathogenesis of diabetic complications. In: Clinical Chemistry. 1986 ; Vol. 32, No. 10 Suppl.
@article{4e8cc71d879746f3beb0df649f0675a8,
title = "Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications.",
abstract = "Prolonged hyperglycemia is the primary metabolic abnormality responsible for the development of irreversible tissue damage in chronic diabetes. However, patients with similar levels of chronic hyperglycemia can differ markedly in their susceptibility to diabetic complications. Among the mechanisms by which hyperglycemia may lead to tissue damage, nonenzymatic glycosylation involves excessive chemical attachment of glucose to proteins without the involvement of enzymes. The early Amadori products, resembling hemoglobin A1c, slowly give rise to complex irreversible glycosylation adducts. Only these post-Amadori products accumulate in diabetic tissues over long periods. However, early nonenzymatic glycosylation or Amadori product formation can alter such physiological processes as enzyme activity or binding of regulatory molecules. Advanced glycosylation end products can covalently trap extravasated serum proteins to the extravascular matrix, and thus may contribute to capillary closure in the retina and glomerulus, and to arterial narrowing in the coronary, cerebral, and peripheral circulation. Although a macrophage receptor system may antagonize this glycosylation-mediated accumulation of proteins by recognizing and ingesting those proteins with advanced glycosylation end products, excessive formation of those proteins in diabetes may saturate the capacity of the macrophage removal system.",
author = "H. Vlassara and M. Brownlee and A. Cerami",
year = "1986",
month = "10",
language = "English (US)",
volume = "32",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "10 Suppl",

}

TY - JOUR

T1 - Nonenzymatic glycosylation

T2 - role in the pathogenesis of diabetic complications.

AU - Vlassara, H.

AU - Brownlee, M.

AU - Cerami, A.

PY - 1986/10

Y1 - 1986/10

N2 - Prolonged hyperglycemia is the primary metabolic abnormality responsible for the development of irreversible tissue damage in chronic diabetes. However, patients with similar levels of chronic hyperglycemia can differ markedly in their susceptibility to diabetic complications. Among the mechanisms by which hyperglycemia may lead to tissue damage, nonenzymatic glycosylation involves excessive chemical attachment of glucose to proteins without the involvement of enzymes. The early Amadori products, resembling hemoglobin A1c, slowly give rise to complex irreversible glycosylation adducts. Only these post-Amadori products accumulate in diabetic tissues over long periods. However, early nonenzymatic glycosylation or Amadori product formation can alter such physiological processes as enzyme activity or binding of regulatory molecules. Advanced glycosylation end products can covalently trap extravasated serum proteins to the extravascular matrix, and thus may contribute to capillary closure in the retina and glomerulus, and to arterial narrowing in the coronary, cerebral, and peripheral circulation. Although a macrophage receptor system may antagonize this glycosylation-mediated accumulation of proteins by recognizing and ingesting those proteins with advanced glycosylation end products, excessive formation of those proteins in diabetes may saturate the capacity of the macrophage removal system.

AB - Prolonged hyperglycemia is the primary metabolic abnormality responsible for the development of irreversible tissue damage in chronic diabetes. However, patients with similar levels of chronic hyperglycemia can differ markedly in their susceptibility to diabetic complications. Among the mechanisms by which hyperglycemia may lead to tissue damage, nonenzymatic glycosylation involves excessive chemical attachment of glucose to proteins without the involvement of enzymes. The early Amadori products, resembling hemoglobin A1c, slowly give rise to complex irreversible glycosylation adducts. Only these post-Amadori products accumulate in diabetic tissues over long periods. However, early nonenzymatic glycosylation or Amadori product formation can alter such physiological processes as enzyme activity or binding of regulatory molecules. Advanced glycosylation end products can covalently trap extravasated serum proteins to the extravascular matrix, and thus may contribute to capillary closure in the retina and glomerulus, and to arterial narrowing in the coronary, cerebral, and peripheral circulation. Although a macrophage receptor system may antagonize this glycosylation-mediated accumulation of proteins by recognizing and ingesting those proteins with advanced glycosylation end products, excessive formation of those proteins in diabetes may saturate the capacity of the macrophage removal system.

UR - http://www.scopus.com/inward/record.url?scp=0002602893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002602893&partnerID=8YFLogxK

M3 - Article

C2 - 3530538

AN - SCOPUS:0002602893

VL - 32

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 10 Suppl

ER -